Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.79 |
| ▸ | CHUK | O15111 | 13/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 9/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568353 | 0.88 | HSP90AB1 (1.00) | HSP90AB1CHUKIKBKBKCNH2 | |
| SCHEMBL12161115 | 0.80 | HSP90AB1 (0.68) | HSP90AB1CHUKIKBKBKCNH2 | |
| SCHEMBL12161196 | 0.80 | HSP90AB1 (0.68) | HSP90AB1CHUKIKBKBKCNH2 | |
| SCHEMBL2566751 | 0.78 | HSP90AB1 (0.61) | HSP90AB1CHUKLRRK2KCNH2 | |
| SCHEMBL2563192 | 0.78 | HSP90AB1 (0.65) | HSP90AB1CHUKIKBKBKCNH2 | |
| SCHEMBL2563404 | 0.77 | HSP90AB1 (1.00) | HSP90AB1CHUKLRRK2KCNH2 | |
| SCHEMBL31296689 | 0.77 | HSP90AB1 (1.00) | HSP90AB1CHUKLRRK2KCNH2 | |
| SCHEMBL14421907 | 0.76 | CHUK (0.61) | HSP90AB1CHUKLRRK2KCNH2 | |
| SCHEMBL12160916 | 0.76 | HSP90AB1 (0.64) | HSP90AB1CHUKLRRK2IKBKBKCNH2 | |
| SCHEMBL12161192 | 0.76 | HSP90AB1 (0.67) | HSP90AB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2007767-B1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS R&D LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-2007767-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R&D) LTD (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | HSP90AB1 2/4885CHUK 258/4885LRRK2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.